A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study

Keyphrases

• Asia 100%
• Randomized Placebo-controlled Trial 100%
• Chronic Migraine 100%
• Dragon 100%
• Erenumab 100%
• Placebo 72%
• Monthly Migraine Days 54%
• Treatment Phase 27%
• Placebo Groups 18%
• Adjusted Means 18%
• Migraine Disability Assessment 18%
• Change from Baseline 18%
• Acute Headache 18%
• Taiwan 9%
• Asian Countries 9%
• Philippines 9%
• Assessment Score 9%
• Thailand 9%
• Singapore 9%
• South Korea 9%
• Mainland China 9%
• Vietnam 9%
• Demographic Characteristics 9%
• Patient-completed 9%
• Overall Characteristics 9%
• China-India 9%
• Asian Region 9%
• Trial Registration 9%
• Malaysia 9%
• Country or Region 9%
• Baseline Characteristics 9%
• Tolerability 9%
• Constipation 9%
• Migraine Duration 9%
• Randomized Double-blind Placebo-controlled Study 9%
• Safety Signal 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Transformed Migraine 100%
• Placebo-Controlled Study 100%
• Erenumab 100%
• Placebo 90%
• Migraine 81%
• Headache 18%
• Disability 18%
• Constipation 9%
• Tolerability 9%

Medicine and Dentistry

• Transformed Migraine 100%
• Placebo-Controlled Study 100%
• Erenumab 100%
• Placebo 90%
• Migraine 63%
• Headache 18%
• MIDAS (Migraine) 18%
• Constipation 9%